Stereotactic boost on residual disease after external-beam irradiation in clinical stage III non-small cell lung cancer: mature results of stereotactic body radiation therapy post radiation therapy (SBRTpostRT) study.
Silvana ParisiGianluca FeriniSara LilloAnna BrognaFederico ChillariGiacomo FerrantelliNicola SettineriAnna SantacaterinaAngelo PlataniaSalvatore LeottaGiuseppe CasablancaAlessandro RussoAntonio PontorieroVincenzo AdamoFabio MinutoliAntonio BottariAlberto CacciolaStefano PergolizziPublished in: La Radiologia medica (2023)
We confirm that a stereotactic boost after radical irradiation is feasible in stage III NSCLC patients. All fit patients who have no indication to adjuvant immunotherapy and presenting residual disease after curative irradiation could benefit from stereotactic boost because outcomes seem to be better than might be historically assumed.
Keyphrases
- radiation therapy
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- prognostic factors
- type diabetes
- small cell lung cancer
- peritoneal dialysis
- radiation induced
- squamous cell carcinoma
- patient reported outcomes
- brain metastases
- tyrosine kinase
- advanced non small cell lung cancer
- patient reported